CD8A and breast cancer: Compound 182 effectively repressed the growth of AT3-OVA mammary tumors (Fig. 3a) and this was accompanied by increased TILs (Fig. 3b, c), including increased CD44hiCD62Llo effector/memory and CD44hiCD62Lhi central memory CD4+ and CD8+ T cells (Fig. 3b; Supplementary Fig. 8b; Supplementary Fig. 9).